Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon's 2023 Annual UK Symposium: New Approaches to Facilitate Drug Discovery

2023-03-30
|
Page View:

                                           Medicilon's 2023 Annual UK Symposium  New Approaches to Facilitate Drug Discovery.jpg

New approaches applied to drug discovery by the medical community and pharmaceutical industry have a direct impact on the development of improved, novel, and curative therapies for patients. Medicilon’s 2023 Annual UK Symposium: New Approaches to Facilitate Drug Discovery will be starting soon. Please join us at the Babraham Research Campus, King's Hedges room for registration at 12:00 pm. We look forward to seeing you!

Date: Friday, April 21st,12:00-18:00 pm
Location: Babraham Research Campus, King's Hedges room 

Meet with Medicilon
Subject丨New Approaches to Facilitate Drug Discovery

Registration

Please scan to register or click the link below to register, we will notify you prior to the event!

code.jpg

https://www.eventbrite.com/e/596362806207 

Agenda

Medicilon's 2023 Annual UK Symposium  New Approaches to Facilitate Drug Discovery agenda.jpg

About Medicilon 

Medicilon is an integrated contract research organization (CRO) providing comprehensive one-stop services from initial idea to IND enabling studies and API manufacture for biotech, pharmaceutical companies and research institutions. With over 19 years’ experience in serving drug discovery, we have built an integrated technical platform covering, small molecule and large molecule drug discovery, in vivo and in vitro pharmacology, and preclinical IND enabling capabilities, to support drug development for today’s dynamic industry.

Our clients include not only pharmaceutical companies such as Roche, GSK and AZ, but also many global SMEs including start-up companies, R&D companies and Universities. Medicilon delivers both non-GLP and GLP safety studies generating data that is fully accepted by FDA, EMA, NMPA and TGA agencies. Our GLP in vivo laboratory is an AAALAC accredited international standard laboratory, audited and approved by NMPA and FDA. Since 2015, Medicilon has successfully assisted 331 new drug and generic drug projects to enter clinical trials by NMPA, FDA, and TGA, which accelerates the customer's new drug development process!

At Medicilon, we offer a full range of preclinical CRO services covering all phases of a client’s project. Customers can work with us via different business models including FFS, FTE or special flexible payment structures designed to help small biotech companies with cash flow and to achieve tight project delivery timelines. Medicilon is a dedicated CRO service provider without any internal drug discovery projects. Throughout 19 year history, Medicilon has fully respected customer Intellectual property.

Medicilon develops new technology platforms constantly, working in partnership with our global clients to deliver demanding and innovative novel drug research. Up to 2022, Medicilon has successfully developed more than 100 preclinical candidates for our global clients. In the preclinical candidate stage, Medicilon screens out lead compounds with high activity and selectivity through high-throughput screening and AI design, and further optimize the lead compounds (including physicochemical properties, early druggability, metabolic stability, pharmacokinetics, toxicity prediction, etc.) to obtain the candidate compound (PCC) and back-up compound, to further enable the research work in the IND stage.

At Medicilon, we are passionate about our role in novel drug discovery and research to improve people's health. We focus on timelines and applying multidisciplinary perspective in resolving our global clients’ research challenges and providing cost effective solutions to deliver quality data in every stage of drug research and development.

19+ years R&D Experience Since 2004

268 New Drugs Approved by NMPA, FDA, EMA, and TGA

1710+ Clients Worldwide

3500+ Scientists & Research staff

87,500+ m2 Laboratories and Facilities 

Speakers

S.jpg

 Shaun McNulty, Ph.D., Senior Scientific Project Adviser 

Shaun is an experienced drug discoverer with over 30 years of experience in the biotechnology and pharmaceutical sectors. He is an experienced biotechnology executive, specialising in drug development strategy and the successful transfer of drug candidates into clinical trials. Shaun obtained his doctorate in kinase-mediated signalling from the University of York and undertook post-doctoral research on neuronal signalling pathways at the University of Cambridge. He then held positions of increasing seniority for Pfizer and GSK, managing development teams and small molecule programmes for preclinical development. He moved into the Biotechnology sector in 2006, joining Syntaxin to direct their discovery portfolio. He then moved to ImmBio, directing scientific collaborations and fundraising. Shaun has worked as a biotech executive for 9 years first as Biosceptre’s CSO, then working for Inflection and Awakn Life Sciences. He worked in the contract research sector as a Director of Biology for Charles River.

D.jpg

Xuedong Dai, Ph.D, Executive VP and Head of IDSU

As a doctor of organic chemistry then as a post doctoral researcher at the Massachusetts Institute of Technology, Xuedong has been deeply engaged in the research and development of chemical drugs for central nervous system diseases, infectious diseases and tumor diseases for more than 20 years. Xuedong has a deep understanding and rich practical experience in the process of drug discovery, including the determination and optimization of precursor compounds, and the successful development of high-quality clinical candidate compounds.
Dr. Xuedong Dai has been involved in leading the development of marketed drugs such as HORIZANT®/REGNITE®; clinical drugs such as JNJ-75276617 and clinical candidates such as ARBACLOFEN PLACARBIL, XP21279, XP23829.
Prior to joining Medicilon, Dr. Dai served as an executive at Xi'an Janssen, Pfeiffer Biotech, GSK, Xenoport and other well-known domestic and international pharmaceutical companies and CROs. He has an excellent project management record and extensive management experience.

C.jpg

Baohong Cao, Ph.D., VP of Pharmacology Department

Receiving his Doctor of Medicine from Beijing Medical University. Dr. Baohong Cao has been engaged in research at the Danish National Serum Institute, the University of Pittsburgh and Pittsburgh Children's Hospital in the United States and the Benaroya Institute in the United States. He has published 24 papers in top academic journals including Natural Cell Biology, Nature Biotechnology, and the Journal of Cell Biology. His research projects have twice been funded by the National Institutes of Health (NIH R01).
Before joining Medicilon, Dr. Baohong Cao served as the senior director of immune oncology of WuXi AppTec US Branch, the director of research and operation of MI BIORESEARCH (now acquired by Covance), and senior manager of Shanghai Ruizhi Chemical Research Co., Ltd. and Novartis (China) Biomedical Research Center. With more than 25 years of medical research and development experience and more than 10 years of team management experience, Dr. Cao has delivered significant achievements in the field of drug discovery, especially in the development of tumor disease models and CAR-T cell therapy.

M.jpg

Marshal Ma, VP of Strategic Alliance & Business Development

Marshal Ma has over 30 years’ experience for international business and technology brokerage in the life sciences industry, facilitating and negotiating partnership deals among UK, Europe and Global biotech companies with China based large biopharmaceutical, healthcare and MedTech companies.
Over the years Marshal Ma as MD of UK Cambridge based technology brokerage company, successfully negotiated many licensed partnership deals between European biotech companies and China biopharmaceutical companies. Deals include, September 2022 Neovii and Fosun Pharma signed an Exclusive Agreement for Development and Commercialization for Grafalon in China; March 2020 Sareum Signed Global Licensing Deal for its FLT3+Aurora Kinase Inhibitor Programme with a China- based Specialty Pharma Company; March 2019 Babraham-based ImmBio signed deal with CNBG/Sinopharm to develop pneumococcal disease vaccine.
Since working with Medicilon on strategic alliance and business development project, Marshal combined China licensed partnership deal making with Medicilon CRO services to better serve biotech and pharma companies. Marshal worked on different preclinical projects commissioned by pharma, biotech and leading European CDMOs, coordinated with Medicilon research team to carry out successful PD, PK and safety studies with quality study reports delivered to meet the requirements of FDA, TGA, EMA and NMPA. 

Overview of Medicilon R&D technology platforms

3.png

Featured Platform-PROTAC

PROTACs offer a fast and reversible chemical knock-down approach to control protein function in the cell. The impact of the PROTAC platform has changed the landscape of drug discovery and development. Medicilon’s PROTAC drug discovery technology platform covers many of the popular target protein ligands. We have established an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, we can efficiently synthesize highly active PROTAC bispecific small molecules, which have the potential to significantly facilitate the drug development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages. Medicilon’s strong technical expertise and flexible service models allow individualized and customized projects ranging from sole chemical synthesis to in vitro and/or in vivo service, and to more comprehensive integrated package support. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 3 PROTAC drugs by NMPA and/or FDA and has more than 20 PROTAC projects under development.

Medicilon has:
• Know-how: > 6 years PROTACs experience
• Comprehensiveness: > 20 ongoing projects
• Talent: > 300 dedicated well-trained chemists
• Team: > 300 dedicated well-trained chemists
• Building Block: > 300 advanced linkers Available
• Scaffold: > 150 E3 ligands available including Cereblon, VHL, MDM2, IAP, etc.

Featured Platform-ADC

Medicilon started ADC non-clinical research in 2014. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 13 ADC drugs by NMPA and/or FDA and has more than 10 ADC projects under development. Up to now, Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins.

Featured Platform-Antibody

With the development of antibody technology, antibody now presents a good development prospect. While major companies are deploying antibody product research and development, they also pay great attention to what needs to be paid attention to and considered in the biological analysis of antibody. Regulations and technical points. The Pharmaceutical Analysis Department of Medicilon Biotechnology is committed to tailoring Case by Case biological analysis methods for customers. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 17 monoclonal antibody drugs and 7 bispecific antibody drugs by NMPA, FDA, and TGA.

#drugdiscovery #babraham #PROTAC #ADC #antibody

Return
Relevant newsRelevant news